Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Fortress Biotech, Inc.

Fortress Biotech (FBIO) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.73 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -48.39%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.44 per share when it actually produced a loss of $0.48, delivering a surprise of -9.09%.
Over the last four quarters, the company has surpassed consensus EPS estimates just once.
Fortress Biotech, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $16.41 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 13.66%. This compares to year-ago revenues of $14.9 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Fortress Biotech shares have lost about 4.7% since the beginning of the year versus the S&P 500's gain of 10%.
What's Next for Fortress Biotech?
While Fortress Biotech has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Fortress Biotech was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.24 on $19.88 million in revenues for the coming quarter and -$1.29 on $103.09 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Phibro Animal Health (PAHC), another stock in the broader Zacks Medical sector, has yet to report results for the quarter ended June 2025.
This maker of animal health products and nutritional supplements is expected to post quarterly earnings of $0.52 per share in its upcoming report, which represents a year-over-year change of +26.8%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Phibro Animal Health's revenues are expected to be $361.15 million, up 32.2% from the year-ago quarter.
Should You Invest in Fortress Biotech, Inc. (FBIO)?
Before you invest in Fortress Biotech, Inc. (FBIO), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Fortress Biotech (FBIO) Reports Q2 Loss, Beats Revenue Estimates

Exelixis (EXEL) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 47.62%. A quarter ago, it was expected that this drug developer would post earnings of $0.51 per share when it actually produced earnings of $0.55, delivering a surprise of 7.84%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Exelixis, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $555.45 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 10.44%. This compares to year-ago revenues of $425.23 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Exelixis shares have added about 11.1% since the beginning of the year versus the S&P 500's decline of -0.6%.
What's Next for Exelixis?
While Exelixis has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Exelixis: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.55 on $547.83 million in revenues for the coming quarter and $2.31 on $2.25 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
One other stock from the same industry, Fortress Biotech (FBIO), is yet to report results for the quarter ended March 2025.
This biopharmaceutical company is expected to post quarterly loss of $0.44 per share in its upcoming report, which represents a year-over-year change of +57.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Fortress Biotech's revenues are expected to be $10.3 million, down 21% from the year-ago quarter.
Should You Invest in Exelixis, Inc. (EXEL)?
Before you invest in Exelixis, Inc. (EXEL), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
Fortress Biotech, Inc. (FBIO) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Exelixis (EXEL) Surpasses Q1 Earnings and Revenue Estimates

Fortress Biotech (FBIO) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.79. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 67.09%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.27 per share when it actually produced a loss of $0.76, delivering a surprise of -181.48%.
Over the last four quarters, the company has surpassed consensus EPS estimates three times.
Fortress Biotech, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $15.12 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by 12.58%. This compares to year-ago revenues of $19.95 million. The company has not been able to beat consensus revenue estimates over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Fortress Biotech shares have lost about 20.5% since the beginning of the year versus the S&P 500's decline of -5.1%.
What's Next for Fortress Biotech?
While Fortress Biotech has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Fortress Biotech: mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.47 on $11.84 million in revenues for the coming quarter and -$1.13 on $155.67 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Gilead Sciences (GILD), has yet to report results for the quarter ended March 2025. The results are expected to be released on April 24.
This HIV and hepatitis C drugmaker is expected to post quarterly earnings of $1.73 per share in its upcoming report, which represents a year-over-year change of +231.1%. The consensus EPS estimate for the quarter has been revised 0% higher over the last 30 days to the current level.
Gilead Sciences' revenues are expected to be $6.8 billion, up 1.7% from the year-ago quarter.
Should You Invest in Fortress Biotech, Inc. (FBIO)?
Before you invest in Fortress Biotech, Inc. (FBIO), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.
Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Fortress Biotech, Inc. (FBIO) : Free Stock Analysis Report
Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Fortress Biotech (FBIO) Reports Q4 Loss, Lags Revenue Estimates

(RTTNews) - Sun Pharmaceutical Industries Limited agreed to acquire Checkpoint Therapeutics Inc. (CKPT), an immunotherapy and targeted oncology company.
As per the deal, Checkpoint stockholders will receive, for each share of common stock they hold, an upfront cash payment of $4.10, without interest, and a non-transferable contingent value right (CVR) entitling the stockholder to receive up to an additional $0.70 in cash, without interest, if cosibelimab is approved prior to certain deadlines in the European Union pursuant to the centralized approval procedure or in Germany, France, Italy, Spain or the United Kingdom.
The cash payment of $4.10 represents aggregate upfront consideration of up to $355 million. It represents a premium of about 66.0% to Checkpoint's closing share price on March 7, 2025, the last trading day prior to today's announcement.
Checkpoint is a commercial-stage company focused on developing novel treatments for patients with solid tumor cancers. Checkpoint has received approval from the U.S. Food & Drug Administration (FDA) for UNLOXCYT (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation.
In connection with the transaction, Checkpoint, Sun Pharma and Fortress Biotech, Inc., Checkpoint's controlling stockholder (FBIO), have entered into a royalty agreement, under which following the closing of the transaction Fortress would be entitled to receive royalty payments based on future sales of cosibelimab during a specified term, in lieu of royalty rights that were granted to Fortress in connection with its founding of Checkpoint.
The transaction is expected to be completed in the second calendar quarter of 2025.
In connection with the transaction, Fortress, which holds a majority of Checkpoint's outstanding voting power, has agreed to vote in favor of the transaction.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Sun Pharmaceutical Industries Agrees To Acquire Checkpoint Therapeutics

(RTTNews) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 05.49 A.M. ET).
In the Green
Safe and Green Development Corporation (SGD) is up over 117% at $6.58. Mural Oncology plc (MURA) is up over 109% at $7.95. Syntec Optics Holdings, Inc. (OPTX) is up over 51% at $7.82. The Gap, Inc. (GPS) is up over 17% at $16.01. Coherus BioSciences, Inc. (CHRS) is up over 12% at $1.93. Fortress Biotech, Inc. (FBIO) is up over 11% at $1.60. Collective Audience, Inc. (CAUD) is up over 10% at $1.94. Innoviz Technologies Ltd. (INVZ) is up over 7% at $1.98. Ross Stores, Inc. (ROST) is up over 6% at $128.01. American Lithium Corp. (AMLI) is up over 6% at $1.24. American Well Corporation (AMWL) is up over 5% at $1.44.
In the Red
ChargePoint Holdings, Inc. (CHPT) is down over 24% at $2.36. Alpha Technology Group Limited (ATGL) is down over 18% at $24.33. HNR Acquisition Corp (HNRA) is down over 10% at $2.68. PaxMedica, Inc. (PXMD) is down over 10% at $1.80. ABVC BioPharma, Inc. (ABVC) is down over 10% at $1.43. Safety Shot, Inc. (SHOT) is down over 9% at $2.63. Applied Materials, Inc. (AMAT) is down over 7% at $143.70. WaveDancer, Inc. (WAVD) is down over 6% at $2.60. reAlpha Tech Corp. (AIRE) is down over 5% at $11.46.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Pre-market Movers: SGD, MURA, OPTX, CHPT, ATGL…

The average one-year price target for Fortress Biotech (NASDAQ:FBIO) has been revised to 7.79 / share. This is an increase of 6.11% from the prior estimate of 7.34 dated August 31, 2023.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 2.02 to a high of 25.20 / share. The average price target represents an increase of 2,413.81% from the latest reported closing price of 0.31 / share.
What is the Fund Sentiment?
There are 68 funds or institutions reporting positions in Fortress Biotech. This is a decrease of 10 owner(s) or 12.82% in the last quarter. Average portfolio weight of all funds dedicated to FBIO is 0.03%, a decrease of 37.45%. Total shares owned by institutions decreased in the last three months by 15.74% to 24,359K shares. The put/call ratio of FBIO is 0.01, indicating a bullish outlook.
What are Other Shareholders Doing?
Nantahala Capital Management holds 6,391K shares representing 4.80% ownership of the company. In it's prior filing, the firm reported owning 6,918K shares, representing a decrease of 8.25%. The firm decreased its portfolio allocation in FBIO by 21.80% over the last quarter.
Opaleye Management holds 3,310K shares representing 2.49% ownership of the company. In it's prior filing, the firm reported owning 4,574K shares, representing a decrease of 38.18%. The firm decreased its portfolio allocation in FBIO by 61.23% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 2,147K shares representing 1.61% ownership of the company. No change in the last quarter.
VEXPX - VANGUARD EXPLORER FUND Investor Shares holds 1,732K shares representing 1.30% ownership of the company. No change in the last quarter.
Perkins Capital Management holds 1,419K shares representing 1.07% ownership of the company. No change in the last quarter.
Fortress Biotech Background Information
(This description is provided by the company.)
Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company that was ranked in Deloitte's 2019 and 2020 Technology Fast 500™, annual rankings of the fastest- growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high- potential marketed and development-stage drugs and drug candidates. The company has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company's portfolio of product opportunities. Fortress has established partnerships with some of the world's leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, St. Jude Children's Research Hospital and Nationwide Children's Hospital.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.